Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
94.00K | 306.00K | 268.00K | 82.00K | 25.00K | 36.00K | Gross Profit |
-736.00K | 96.00K | 75.00K | 45.00K | 14.00K | 18.00K | EBIT |
-35.94M | -39.82M | -45.65M | -35.40M | -17.97M | -16.56M | EBITDA |
-31.24M | -35.29M | -42.91M | -33.60M | -17.11M | -13.60M | Net Income Common Stockholders |
-32.24M | -36.24M | -44.25M | -36.23M | -21.61M | -20.44M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
21.39M | 49.08M | 82.70M | 105.11M | 13.53M | 21.39M | Total Assets |
0.00 | 95.44M | 116.33M | 147.03M | 14.80M | 23.26M | Total Debt |
0.00 | 1.86M | 2.31M | 128.00K | 8.67M | 9.31M | Net Debt |
21.39M | -2.02M | -27.57M | -58.80M | -4.86M | -12.07M | Total Liabilities |
0.00 | 25.28M | 17.39M | 8.46M | 140.37M | 129.88M | Stockholders Equity |
10.96M | 70.16M | 98.94M | 138.56M | -125.57M | -106.62M |
Cash Flow | Free Cash Flow | ||||
-15.75M | -27.32M | -35.40M | -32.94M | -17.02M | -19.43M | Operating Cash Flow |
-14.69M | -27.19M | -34.61M | -31.64M | -16.87M | -19.32M | Investing Cash Flow |
4.73M | 438.00K | 5.55M | -82.56M | -149.00K | -6.00K | Financing Cash Flow |
2.99M | 752.00K | 5.00K | 159.59M | 9.16M | 33.05M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | $19.46B | ― | -19.42% | ― | 56.75% | 59.77% | |
53 Neutral | $8.11B | ― | -37.09% | ― | 10.37% | -389.98% | |
51 Neutral | $810.82M | ― | -17.15% | ― | 12.15% | 61.33% | |
51 Neutral | $5.32B | ― | -4584.47% | ― | 31.04% | 16.91% | |
49 Neutral | $12.67B | ― | -30.11% | ― | -2.93% | -4.69% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 19.94% | 1.20% | |
34 Underperform | $133.33M | ― | -55.78% | ― | -74.84% | 14.63% |
On February 10, 2025, Sera Prognostics announced a public offering of its Class A common stock and pre-funded warrants, expecting to raise approximately $50 million. The proceeds are intended to enhance U.S. commercial infrastructure, prepare for EU expansion, and support studies for the PreTRM test, with a potential FDA submission for broader approval.
On January 31, 2025, Sera Prognostics updated its corporate investor presentation to reflect findings from the PRIME study, which emphasizes the significant clinical and economic challenges posed by preterm births. The company’s PreTRM test, validated for use between 18 to 20 weeks of gestation, offers a predictive assessment of preterm birth risk, potentially reducing costs associated with neonatal care. This advancement positions Sera Prognostics as a leader in addressing a crucial healthcare issue, with implications for improved neonatal outcomes and reduced healthcare expenditures.
Sera Prognostics announced the release of a new investor presentation and its participation in the upcoming J.P. Morgan Healthcare Conference. The release highlights the significance of preterm birth as a major health challenge and the company’s innovative approach using proteomics to predict and manage this condition. The PreTRM® Test, validated for use during weeks 18-20 of pregnancy, is emphasized as a critical tool in reducing the clinical and economic burdens of preterm birth, positioning Sera Prognostics as a leader in the prenatal diagnostics space.
On January 6, 2025, a study abstract published by the Society for Maternal Fetal Medicine highlighted the results of the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal Outcomes (PRIME) study. These findings will be further detailed at the SMFM 2025 Pregnancy Meeting and discussed by Sera Prognostics through a conference call on February 6, 2025, indicating the company’s engagement in advancing maternal and fetal health research.